798
Views
9
CrossRef citations to date
0
Altmetric
Reviews

CRISPR/Cas: from adaptive immune system in prokaryotes to therapeutic weapon against immune-related diseases

CRISPR/Cas9 offers a simple and inexpensive method for disease modeling, genetic screening, and potentially for disease therapy

ORCID Icon, &
Pages 11-20 | Received 02 Aug 2019, Accepted 01 Oct 2019, Published online: 18 Oct 2019
 

Abstract

CRISPR/Cas evolved as an adaptive immune system in bacteria and archaea to inactivate foreign viral and plasmid DNA. However, the capacities of various CRISPR/Cas systems for precise genome editing based on sequence homology also allow their use as tools for genomic and epigenomic modification in eukaryotes. Indeed, these genetic characteristics have proven useful for disease modeling and testing the specific functions of target genes under pathological conditions. Moreover, recent studies provide compelling evidence that CRISPR/Cas systems could be useful therapeutic tools against human diseases, including cancer, monogenic disorders, and autoimmune disorders.

    Highlights

  • CRISPR/Cas evolved as an adaptive immune system in bacteria and archaea.

  • CRISPR/Cas systems are nowadays used as tools for genomic modification.

  • CRISPR/Cas systems could be useful therapeutic tools against human disease, including autoimmune conditions.

Disclosure statement

The authors declare no conflict of interest

Acknowledgments

Dr. García extends special appreciation to the Rheumatology team of Fundación Valle del Lili in Cali, Colombia, for support during medical training as well as to the research group on rheumatology, autoimmunity and translational medicine (GIRAT) at Universidad Icesi (Gabriel J. Tobón MD PhD, Carlos Cañas MD, David Aguirre MD, Erika Navarro MD, Alex Echeverri MD and Anilza Bonelo PhD). Dr. Garcia also wants to thank Natalia Arango Mesa MD for the support. All authors thank Lady J. Rios-Serna BSc from GIRAT for assistance in graphic design, and Adolfo Abadía (Universidad Icesi) for Editorial Support.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.